Skip to main content
TipRanks
Go Ultimate75% OFF

TTY Biopharm Company Limited (4105) AI Stock Analysis

TW:4105

TTY Biopharm Company Limited

(TPEx:4105)

Select Model
Rating:62Neutral
Price Target:TWD 84.00â–¼(-0.12% Downside)
Action:initiatedcoverage
Date:11/10/26

The overall score of 62 reflects a company with a fortress-like balance sheet and strong cash generation that is overshadowed by a severe operational crisis. The primary risk is the 82.6% revenue collapse, which calls into question the sustainability of future earnings and the current dividend. While the low P/E and high dividend yield are attractive, they may be a value trap. The technical trend is neutral, offering no clear directional signal. The company's financial stability provides a floor, but until revenue stabilizes, significant uncertainty remains.

Positive Factors
Strong and durable marginsConsistently high gross, operating, and net margins indicate that TTY Biopharm has maintained meaningful profitability across its prescription pharmaceutical activities. This supports internal reinvestment, provides resilience against operating pressure, and suggests a potentially durable earnings base over the next several quarters.
Negative Factors
Severe 2025 revenue declineThe sharp 2025 revenue contraction is a material challenge to earnings durability, even though margins remained strong. If the decline reflects product-cycle timing, demand instability, or one-off revenue effects, future growth and the utilization of the company’s commercial platform may remain difficult to forecast.

TTY Biopharm Company Limited (4105) vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%TW:4105+13.81%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 20.91B
Dividend Yield
5.35%
Average Volume (3M)
640.28K
Price to Earnings (P/E)
12.6
Beta (1Y)
0.19
Revenue Growth
4.54%
EPS Growth
-7.38%
Country
TW
Employees
561
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

TTY Biopharm Company Limited Business Overview & Revenue Model

Company Description

TTY Biopharm Company Limited, along with its associated entities, specializes in the creation and distribution of pharmaceutical and chemical products across Taiwan and global markets. Its operations are structured into several key divisions: Oncolog...

TTY Biopharm Company Limited Financial Statement Overview

Summary

Financial health is a tale of two halves. The balance sheet is excellent with very low debt (D/E 0.17) and strong ROE (21.5%), while cash flow conversion is robust at over 91%. However, the income statement reveals a catastrophic 82.6% revenue collapse, creating major uncertainty. The strong capital structure provides a buffer, but the operational crisis significantly drags down the overall financial score.

Income Statement

45Neutral

Balance Sheet

78Positive

Cash Flow

68Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.80B6.45B5.89B5.51B5.06B4.54B
Gross Profit3.95B3.72B3.41B3.22B3.02B2.77B
EBITDA2.12B1.90B1.73B1.66B1.50B1.14B
Net Income1.68B1.56B1.45B1.13B1.09B831.89M
Balance Sheet
Total Assets12.24B11.35B10.86B9.87B9.60B9.30B
Cash, Cash Equivalents and Short-Term Investments2.80B2.99B3.08B2.82B2.68B2.59B
Total Debt1.88B1.23B1.76B1.92B1.87B2.20B
Total Liabilities3.92B3.30B3.35B3.37B3.37B3.53B
Stockholders Equity7.47B7.24B6.75B5.94B5.66B5.17B
Cash Flow
Free Cash Flow1.56B1.61B1.22B985.73M1.10B1.18B
Operating Cash Flow1.71B1.76B1.35B1.09B1.24B1.26B
Investing Cash Flow-382.19M-367.36M-243.56M-2.63M-133.14M-168.78M
Financing Cash Flow-1.34B-1.59B-1.05B-816.33M-1.10B-850.05M

TTY Biopharm Company Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:4105 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:6620TW:662070OutperformTWD 19.75B59.19―1.74%――
TW:3705TW:370569NeutralTWD 15.66B16.52―5.10%-5.14%-1.33%
TW:4105TW:410562NeutralTWD 20.91B12.63―5.35%4.54%-7.38%
TW:1789TW:178957NeutralTWD 15.58B891.40―1.47%-4.75%-91.36%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:4123TW:412348NeutralTWD 22.90B-15.51―6.04%13.63%-186.87%
TW:4743TW:474342NeutralTWD 24.07B-107.35――18.66%84.62%

* General Sector Average

Performance Comparison

-25%0%25%50%TW:4105TW:1789TW:3705TW:4123TW:4743TW:6620Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:4105 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:4105TTY Biopharm Company Limited84.1010.6814.54%
TW:1789Scinopharm Taiwan, Ltd.19.702.9417.53%
TW:3705YungShin Global Holding Corp.58.806.8813.26%
TW:4123Center Laboratories, Inc.28.90-3.69-11.31%
TW:4743Oneness Biotech Co., Ltd.50.20-7.40-12.85%
TW:6620Handa Pharmaceuticals Inc119.005.354.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026